Computed tomography‐guided intraluminal brachytherapy in recurrent bronchogenic carcinoma: A clinical trial in a small group

Objective The overall survival (OS) of lung cancer patients has been significantly extended as a consequence of chemotherapy and targeted drug utilization, which has resulted in an increase in local recurrences. The present study followed patients to evaluate the short‐term and long‐term efficacies...

Full description

Saved in:
Bibliographic Details
Published in:Precision radiation oncology 2017-06, Vol.1 (2), p.52-57
Main Authors: Ma, Chenying, Xu, Xiaoting, Zhang, Ruting, Qin, Songbing, Zhou, Juying
Format: Article
Language:English
Subjects:
Airway management
Cancer therapies
Chemotherapy
Clinical trials
Cryotherapy
Dyspnea
external beam radiation therapy
high‐dose rate
Injuries
intraluminal brachytherapy
Lung cancer
lung neoplasms
palliative care
Patients
Quality of life
Radiation therapy
Studies
Surgery
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2278-7cb39677864bffa9bca0685773b4ae291edb3897dc5c09b4990f6179a08282933
container_end_page 57
container_issue 2
container_start_page 52
container_title Precision radiation oncology
container_volume 1
creator Ma, Chenying
Xu, Xiaoting
Zhang, Ruting
Qin, Songbing
Zhou, Juying
description Objective The overall survival (OS) of lung cancer patients has been significantly extended as a consequence of chemotherapy and targeted drug utilization, which has resulted in an increase in local recurrences. The present study followed patients to evaluate the short‐term and long‐term efficacies and the safety of high‐dose rate intraluminal brachytherapy (ILBT) in recurrent bronchogenic carcinoma patients, and investigate the factors that influence prognosis. Methods The clinical records, treatment, curable effects, and adverse events of 15 patients treated in the First Affiliated Hospital of Soochow University, Suzhou, China, who were diagnosed with recurrent bronchogenic cancer between 1 June 2009 and 30 September 2015 were reviewed, and survival analysis was assessed by the Kaplan–Meier method. Results A total of 15 recurrent bronchogenic carcinoma patients received ILBT, and information on curable effects and safety was available. The group consisted of two complete response (2/15), 11 partial response (11/15), one stable disease (1/15) and one progression disease (1/15). The response rate was 86.7% (13/15), and disease control (complete response + partial response + stable disease) was 93.3% (14/15). The dyspnea indexes of the patients decreased significantly in weeks 1, 2, 4, and 8 after ILBT treatment (P 
doi_str_mv 10.1002/pro6.18
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2290171289</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2290171289</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2278-7cb39677864bffa9bca0685773b4ae291edb3897dc5c09b4990f6179a08282933</originalsourceid><addsrcrecordid>eNp1kM9KxDAQxoMouKyLrxDw4EF2TdJuk3hbFv_BworoOaRp2mZpm5o0SC_iI_iMPolZ1oMXLzPDN78ZZj4AzjFaYITIde9stsDsCExIwtmcJiQ9_lOfgpn3O4QQ5gQtaToBH2vb9mHQBRxsaysn-3r8_vyqgimiZrrBySa0ppMNzJ1U9TjUOkJjbEGnVXBOd0Ns2U7VttKdUVBJp0xnW3kDV1A1JmpxenAmxjgloW9l08DK2dCfgZNSNl7PfvMUvN7dvqwf5pvt_eN6tZkrQmi8XeUJzyhlWZqXpeS5kihjS0qTPJWacKyLPGGcFmqpEM9TzlGZYcolYoQRniRTcHHYGw16C9oPYmeDi195QQhHmGLCeKQuD5Ry1nunS9E700o3CozE3l-x91dgFsmrA_luGj3-h4mn520W6R8KlX5J</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290171289</pqid></control><display><type>article</type><title>Computed tomography‐guided intraluminal brachytherapy in recurrent bronchogenic carcinoma: A clinical trial in a small group</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><creator>Ma, Chenying ; Xu, Xiaoting ; Zhang, Ruting ; Qin, Songbing ; Zhou, Juying</creator><creatorcontrib>Ma, Chenying ; Xu, Xiaoting ; Zhang, Ruting ; Qin, Songbing ; Zhou, Juying</creatorcontrib><description>Objective The overall survival (OS) of lung cancer patients has been significantly extended as a consequence of chemotherapy and targeted drug utilization, which has resulted in an increase in local recurrences. The present study followed patients to evaluate the short‐term and long‐term efficacies and the safety of high‐dose rate intraluminal brachytherapy (ILBT) in recurrent bronchogenic carcinoma patients, and investigate the factors that influence prognosis. Methods The clinical records, treatment, curable effects, and adverse events of 15 patients treated in the First Affiliated Hospital of Soochow University, Suzhou, China, who were diagnosed with recurrent bronchogenic cancer between 1 June 2009 and 30 September 2015 were reviewed, and survival analysis was assessed by the Kaplan–Meier method. Results A total of 15 recurrent bronchogenic carcinoma patients received ILBT, and information on curable effects and safety was available. The group consisted of two complete response (2/15), 11 partial response (11/15), one stable disease (1/15) and one progression disease (1/15). The response rate was 86.7% (13/15), and disease control (complete response + partial response + stable disease) was 93.3% (14/15). The dyspnea indexes of the patients decreased significantly in weeks 1, 2, 4, and 8 after ILBT treatment (P &lt; 0.001). The average post‐ILBT partial remission period was 5.27 ± 3.35 months, and the median partial remission period was 3.24 months. The combination therapy of ILBT and bronchofiberscope (P = 0.013), and a total ILBT dose of ≥20 Gy could produce a partial effective rate. The progress‐free survival of patients was 9.5 months (95% CI 12.2–16.5 months), average progress‐free survival was 15.8 ± 14.4 months, median OS was 32.0 months (95% CI 25.0–30.0 months), 1‐year OS was 93.3% (14/15), and 3‐year OS was 40.0% (6/15). The main adverse events were bronchospasm and hemoptysis (grade III); others were grade I–II. Conclusion Computed tomography‐guided ILBT is a safe, effective palliative treatment for recurrent bronchogenic carcinoma, but it requires further study in larger groups.</description><identifier>ISSN: 2398-7324</identifier><identifier>EISSN: 2398-7324</identifier><identifier>DOI: 10.1002/pro6.18</identifier><language>eng</language><publisher>Shandong: John Wiley &amp; Sons, Inc</publisher><subject>Airway management ; Cancer therapies ; Chemotherapy ; Clinical trials ; Cryotherapy ; Dyspnea ; external beam radiation therapy ; high‐dose rate ; Injuries ; intraluminal brachytherapy ; Lung cancer ; lung neoplasms ; palliative care ; Patients ; Quality of life ; Radiation therapy ; Studies ; Surgery ; Tumors</subject><ispartof>Precision radiation oncology, 2017-06, Vol.1 (2), p.52-57</ispartof><rights>2017 The Authors. published by John Wiley &amp; Sons Australia, Ltd on behalf of Shandong Cancer Hospital &amp; Institute.</rights><rights>2017. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2278-7cb39677864bffa9bca0685773b4ae291edb3897dc5c09b4990f6179a08282933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2290171289/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2290171289?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,778,782,11549,25740,27911,27912,36999,44577,46039,46463,74881</link.rule.ids></links><search><creatorcontrib>Ma, Chenying</creatorcontrib><creatorcontrib>Xu, Xiaoting</creatorcontrib><creatorcontrib>Zhang, Ruting</creatorcontrib><creatorcontrib>Qin, Songbing</creatorcontrib><creatorcontrib>Zhou, Juying</creatorcontrib><title>Computed tomography‐guided intraluminal brachytherapy in recurrent bronchogenic carcinoma: A clinical trial in a small group</title><title>Precision radiation oncology</title><description>Objective The overall survival (OS) of lung cancer patients has been significantly extended as a consequence of chemotherapy and targeted drug utilization, which has resulted in an increase in local recurrences. The present study followed patients to evaluate the short‐term and long‐term efficacies and the safety of high‐dose rate intraluminal brachytherapy (ILBT) in recurrent bronchogenic carcinoma patients, and investigate the factors that influence prognosis. Methods The clinical records, treatment, curable effects, and adverse events of 15 patients treated in the First Affiliated Hospital of Soochow University, Suzhou, China, who were diagnosed with recurrent bronchogenic cancer between 1 June 2009 and 30 September 2015 were reviewed, and survival analysis was assessed by the Kaplan–Meier method. Results A total of 15 recurrent bronchogenic carcinoma patients received ILBT, and information on curable effects and safety was available. The group consisted of two complete response (2/15), 11 partial response (11/15), one stable disease (1/15) and one progression disease (1/15). The response rate was 86.7% (13/15), and disease control (complete response + partial response + stable disease) was 93.3% (14/15). The dyspnea indexes of the patients decreased significantly in weeks 1, 2, 4, and 8 after ILBT treatment (P &lt; 0.001). The average post‐ILBT partial remission period was 5.27 ± 3.35 months, and the median partial remission period was 3.24 months. The combination therapy of ILBT and bronchofiberscope (P = 0.013), and a total ILBT dose of ≥20 Gy could produce a partial effective rate. The progress‐free survival of patients was 9.5 months (95% CI 12.2–16.5 months), average progress‐free survival was 15.8 ± 14.4 months, median OS was 32.0 months (95% CI 25.0–30.0 months), 1‐year OS was 93.3% (14/15), and 3‐year OS was 40.0% (6/15). The main adverse events were bronchospasm and hemoptysis (grade III); others were grade I–II. Conclusion Computed tomography‐guided ILBT is a safe, effective palliative treatment for recurrent bronchogenic carcinoma, but it requires further study in larger groups.</description><subject>Airway management</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Cryotherapy</subject><subject>Dyspnea</subject><subject>external beam radiation therapy</subject><subject>high‐dose rate</subject><subject>Injuries</subject><subject>intraluminal brachytherapy</subject><subject>Lung cancer</subject><subject>lung neoplasms</subject><subject>palliative care</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Studies</subject><subject>Surgery</subject><subject>Tumors</subject><issn>2398-7324</issn><issn>2398-7324</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNp1kM9KxDAQxoMouKyLrxDw4EF2TdJuk3hbFv_BworoOaRp2mZpm5o0SC_iI_iMPolZ1oMXLzPDN78ZZj4AzjFaYITIde9stsDsCExIwtmcJiQ9_lOfgpn3O4QQ5gQtaToBH2vb9mHQBRxsaysn-3r8_vyqgimiZrrBySa0ppMNzJ1U9TjUOkJjbEGnVXBOd0Ns2U7VttKdUVBJp0xnW3kDV1A1JmpxenAmxjgloW9l08DK2dCfgZNSNl7PfvMUvN7dvqwf5pvt_eN6tZkrQmi8XeUJzyhlWZqXpeS5kihjS0qTPJWacKyLPGGcFmqpEM9TzlGZYcolYoQRniRTcHHYGw16C9oPYmeDi195QQhHmGLCeKQuD5Ry1nunS9E700o3CozE3l-x91dgFsmrA_luGj3-h4mn520W6R8KlX5J</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Ma, Chenying</creator><creator>Xu, Xiaoting</creator><creator>Zhang, Ruting</creator><creator>Qin, Songbing</creator><creator>Zhou, Juying</creator><general>John Wiley &amp; Sons, Inc</general><scope>24P</scope><scope>WIN</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201706</creationdate><title>Computed tomography‐guided intraluminal brachytherapy in recurrent bronchogenic carcinoma: A clinical trial in a small group</title><author>Ma, Chenying ; Xu, Xiaoting ; Zhang, Ruting ; Qin, Songbing ; Zhou, Juying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2278-7cb39677864bffa9bca0685773b4ae291edb3897dc5c09b4990f6179a08282933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Airway management</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Cryotherapy</topic><topic>Dyspnea</topic><topic>external beam radiation therapy</topic><topic>high‐dose rate</topic><topic>Injuries</topic><topic>intraluminal brachytherapy</topic><topic>Lung cancer</topic><topic>lung neoplasms</topic><topic>palliative care</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Studies</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Chenying</creatorcontrib><creatorcontrib>Xu, Xiaoting</creatorcontrib><creatorcontrib>Zhang, Ruting</creatorcontrib><creatorcontrib>Qin, Songbing</creatorcontrib><creatorcontrib>Zhou, Juying</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Precision radiation oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Chenying</au><au>Xu, Xiaoting</au><au>Zhang, Ruting</au><au>Qin, Songbing</au><au>Zhou, Juying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Computed tomography‐guided intraluminal brachytherapy in recurrent bronchogenic carcinoma: A clinical trial in a small group</atitle><jtitle>Precision radiation oncology</jtitle><date>2017-06</date><risdate>2017</risdate><volume>1</volume><issue>2</issue><spage>52</spage><epage>57</epage><pages>52-57</pages><issn>2398-7324</issn><eissn>2398-7324</eissn><abstract>Objective The overall survival (OS) of lung cancer patients has been significantly extended as a consequence of chemotherapy and targeted drug utilization, which has resulted in an increase in local recurrences. The present study followed patients to evaluate the short‐term and long‐term efficacies and the safety of high‐dose rate intraluminal brachytherapy (ILBT) in recurrent bronchogenic carcinoma patients, and investigate the factors that influence prognosis. Methods The clinical records, treatment, curable effects, and adverse events of 15 patients treated in the First Affiliated Hospital of Soochow University, Suzhou, China, who were diagnosed with recurrent bronchogenic cancer between 1 June 2009 and 30 September 2015 were reviewed, and survival analysis was assessed by the Kaplan–Meier method. Results A total of 15 recurrent bronchogenic carcinoma patients received ILBT, and information on curable effects and safety was available. The group consisted of two complete response (2/15), 11 partial response (11/15), one stable disease (1/15) and one progression disease (1/15). The response rate was 86.7% (13/15), and disease control (complete response + partial response + stable disease) was 93.3% (14/15). The dyspnea indexes of the patients decreased significantly in weeks 1, 2, 4, and 8 after ILBT treatment (P &lt; 0.001). The average post‐ILBT partial remission period was 5.27 ± 3.35 months, and the median partial remission period was 3.24 months. The combination therapy of ILBT and bronchofiberscope (P = 0.013), and a total ILBT dose of ≥20 Gy could produce a partial effective rate. The progress‐free survival of patients was 9.5 months (95% CI 12.2–16.5 months), average progress‐free survival was 15.8 ± 14.4 months, median OS was 32.0 months (95% CI 25.0–30.0 months), 1‐year OS was 93.3% (14/15), and 3‐year OS was 40.0% (6/15). The main adverse events were bronchospasm and hemoptysis (grade III); others were grade I–II. Conclusion Computed tomography‐guided ILBT is a safe, effective palliative treatment for recurrent bronchogenic carcinoma, but it requires further study in larger groups.</abstract><cop>Shandong</cop><pub>John Wiley &amp; Sons, Inc</pub><doi>10.1002/pro6.18</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2398-7324
ispartof Precision radiation oncology, 2017-06, Vol.1 (2), p.52-57
issn 2398-7324
2398-7324
language eng
recordid cdi_proquest_journals_2290171289
source Wiley Online Library Open Access; Publicly Available Content Database
subjects Airway management
Cancer therapies
Chemotherapy
Clinical trials
Cryotherapy
Dyspnea
external beam radiation therapy
high‐dose rate
Injuries
intraluminal brachytherapy
Lung cancer
lung neoplasms
palliative care
Patients
Quality of life
Radiation therapy
Studies
Surgery
Tumors
title Computed tomography‐guided intraluminal brachytherapy in recurrent bronchogenic carcinoma: A clinical trial in a small group
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T14%3A33%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Computed%20tomography%E2%80%90guided%20intraluminal%20brachytherapy%20in%20recurrent%20bronchogenic%20carcinoma:%20A%20clinical%20trial%20in%20a%20small%20group&rft.jtitle=Precision%20radiation%20oncology&rft.au=Ma,%20Chenying&rft.date=2017-06&rft.volume=1&rft.issue=2&rft.spage=52&rft.epage=57&rft.pages=52-57&rft.issn=2398-7324&rft.eissn=2398-7324&rft_id=info:doi/10.1002/pro6.18&rft_dat=%3Cproquest_cross%3E2290171289%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2278-7cb39677864bffa9bca0685773b4ae291edb3897dc5c09b4990f6179a08282933%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2290171289&rft_id=info:pmid/&rfr_iscdi=true